An observational study in Patient Starting Bevacizumab and Cancer, sponsored by University Hospital, Tours. Completed at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-08.
Sponsored by University Hospital, Tours · Observational
Bevacizumab is an anti-angiogenic treatment used to treat various solid cancers. Previous studies have shown that this treatment may have adverse effects like hypertension and proteinuria.
This is an exploratory study aiming to better understand the relationship between various biomarkers and blood pressure changes and proteinuria measured for 4 to 6 weeks after the first infusion of anti-VEGF therapy with bevacizumab.
Participants will be invited to participate to this research study by their oncologist within 1 to 2 weeks before starting bevacizumab treatment, as part of standard treatment. They will finish the research at the end of the third infusion of bevacizumab.
Patients will perform a home blood pressure self-measurement over three days and will collect urine over 24 hours prior to the start of each bevacizumab infusion at cycles 1, 2 and 3. Blood pressure measurements will also be performed during each bevacizumab infusion and blood tests will be performed before each infusion to measure the following biomarkers:
234 studies on the registry are indexed under Proteinuria; 43 are open to participants now.
This study's enrollment of 26 is below the median of 125 across 53 observational studies indexed under Proteinuria.
Browse Proteinuria studies →University Hospital, Tours is the lead sponsor of 304 studies on the registry; 78 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with solid cancers who will be starting treatment with bevacizumab as part of the standard treatment
Exclusion Criteria:
Taken biological samples (urine and blood) and blood pressure measurement on patients starting bevacizumab treatment for cancer
Other: Biological samples · Other: Blood pressure measurement
Urine and blood samples
Home blood pressure self-measurement and hospital blood pressure measurement
Home blood pressure measurement
Home blood pressure (systolic, diastolic) before each bevacizumab infusion, as the mean of 3 measures in the morning and 3 measures in the evening, over 3 days
Time frame: before the initiation of bevacizumab and before each bevacizumab infusion, up to 10 weeks
in-hospital blood pressure measurement
Standardized measurement of in-hospital blood pressure (systolic, diastolic) and heart rate during bevacizumab infusion
Time frame: before the initiation of bevacizumab and before each bevacizumab infusion, up to 10 weeks
24-hour proteinuria
Measurement of 24 hours proteinuria
Time frame: before the initiation of bevacizumab and before each bevacizumab infusion, up to 10 weeks
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Tours